Symbols / FNCH
FNCH Chart
About
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 21.28M |
| Enterprise Value | 34.41M | Income | -14.17M | Sales | — |
| Book/sh | 8.86 | Cash/sh | 9.99 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.64 | PEG | — |
| P/S | inf | P/B | 1.50 | P/C | — |
| EV/EBITDA | -1.76 | EV/Sales | — | Quick Ratio | 3.59 |
| Current Ratio | 3.87 | Debt/Eq | 203.88 | LT Debt/Eq | — |
| EPS (ttm) | -8.80 | EPS next Y | -20.59 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-08-10 06:00 | ROA | -21.89% |
| ROE | -67.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.61M |
| Shs Float | 1.56M | Short Float | 2.76% | Short Ratio | 0.19 |
| Short Interest | — | 52W High | 16.10 | 52W Low | 11.50 |
| Beta | 1.16 | Avg Volume | 3.50K | Volume | 1.07K |
| Target Price | — | Recom | None | Prev Close | $13.10 |
| Price | $13.25 | Change | 1.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$13.20
Latest analyst target
3. DCF / Fair value
$-178.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.20
Low
—
High
—
Mean
—
- What Makes Finch Therapeutics (FNCH) a Worthy Investment? - Yahoo Finance hu, 11 Dec 2025 08
- Finch Therapeutics: Post-Trial Decision Can Potentially Drive Shares To Trade Higher - Seeking Alpha hu, 06 Feb 2025 08
- Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire Mon, 21 Oct 2024 07
- Finch Therapeutics Group to Delist from Nasdaq - Nasdaq Mon, 21 Oct 2024 07
- Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives - statnews.com Fri, 19 Mar 2021 07
- Finch Therapeutics Group (FNCH) Stock Price, News & Analysis - MarketBeat Fri, 19 Mar 2021 23
- Finch Announces Reverse Stock Split of Common Stock - Yahoo Finance Fri, 09 Jun 2023 07
- Is ROKU Stock a Buy After Earnings? 4 Analysts Weigh In on Roku. - InvestorPlace Fri, 29 Apr 2022 07
- Finch Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire hu, 18 Mar 2021 07
- Here's What Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) Shareholder Ownership Structure Looks Like - Nasdaq hu, 16 Dec 2021 08
- Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND - Yahoo Finance hu, 28 Apr 2022 07
- Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation - Yahoo Finance Wed, 10 Aug 2022 07
- Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 0.6% – Should You Buy? - Defense World ue, 24 Feb 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 767 | — | — | Stock Gift at price 0.00 per share. | SMISEK JEFFERY A | Director | — | 2024-06-07 00:00:00 | D/I |
| 1 | 3750 | — | — | Stock Gift at price 0.00 per share. | SMISEK JEFFERY A | Director | — | 2024-05-20 00:00:00 | I |
| 2 | 8242 | 21246 | — | Sale at price 2.57 - 2.61 per share. | SMISEK JEFFERY A | Director | — | 2024-03-28 00:00:00 | D/I |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | -2.21M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.04 | 0.00 | 0.00 |
| NormalizedEBITDA | 17.35M | -55.28M | -59.54M |
| TotalUnusualItems | -49.84M | -27.41M | 1.85M |
| TotalUnusualItemsExcludingGoodwill | -49.84M | -27.41M | 1.85M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -74.75M | -114.65M | -58.16M |
| ReconciledDepreciation | 1.52M | 5.51M | 2.30M |
| EBITDA | -32.48M | -82.69M | -57.68M |
| EBIT | -34.00M | -88.19M | -59.98M |
| NetInterestIncome | 1.57M | 252.00K | 22.00K |
| InterestIncome | 1.57M | 252.00K | 22.00K |
| NormalizedIncome | -27.13M | -87.24M | -60.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -74.75M | -114.65M | -58.16M |
| TotalExpenses | 34.11M | 89.06M | 78.52M |
| TotalOperatingIncomeAsReported | -83.86M | -115.59M | -59.98M |
| DilutedAverageShares | 1.60M | 1.59M | 1.31M |
| BasicAverageShares | 1.60M | 1.59M | 1.31M |
| DilutedEPS | -46.59 | -72.00 | -44.40 |
| BasicEPS | -46.59 | -72.00 | -44.40 |
| DilutedNIAvailtoComStockholders | -74.75M | -114.65M | -58.16M |
| NetIncomeCommonStockholders | -74.75M | -114.65M | -58.16M |
| NetIncome | -74.75M | -114.65M | -58.16M |
| NetIncomeIncludingNoncontrollingInterests | -74.75M | -114.65M | -58.16M |
| NetIncomeContinuousOperations | -74.75M | -114.65M | -58.16M |
| TaxProvision | -3.46M | 0.00 | 0.00 |
| PretaxIncome | -78.22M | -114.65M | -58.16M |
| OtherIncomeExpense | -45.78M | -26.70M | 1.80M |
| OtherNonOperatingIncomeExpenses | 4.05M | 702.00K | -52.00K |
| SpecialIncomeCharges | -49.84M | -27.41M | 1.85M |
| GainOnSaleOfPPE | 637.00K | -7.00K | 28.00K |
| OtherSpecialCharges | 614.00K | -1.83M | |
| ImpairmentOfCapitalAssets | 46.04M | 24.98M | 0.00 |
| RestructuringAndMergernAcquisition | 3.82M | 2.42M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 1.57M | 252.00K | 22.00K |
| InterestIncomeNonOperating | 1.57M | 252.00K | 22.00K |
| OperatingIncome | -34.00M | -88.19M | -59.98M |
| OperatingExpense | 34.11M | 89.06M | 78.52M |
| ResearchAndDevelopment | 7.20M | 52.86M | 57.28M |
| SellingGeneralAndAdministration | 26.91M | 36.19M | 21.24M |
| GeneralAndAdministrativeExpense | 26.91M | 36.19M | 21.24M |
| OtherGandA | 23.25M | 24.22M | 9.51M |
| SalariesAndWages | 3.66M | 11.97M | 11.73M |
| TotalRevenue | 107.00K | 861.00K | 18.53M |
| OperatingRevenue | 107.00K | 861.00K | 18.53M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 1.61M | 1.60M | 1.58M |
| ShareIssued | 1.61M | 1.60M | 1.58M |
| TotalDebt | 30.13M | 52.34M | 6.01M |
| TangibleBookValue | 22.89M | 62.81M | 151.27M |
| InvestedCapital | 22.89M | 110.36M | 202.22M |
| WorkingCapital | 21.76M | 59.86M | 127.76M |
| NetTangibleAssets | 22.89M | 62.81M | 151.27M |
| CapitalLeaseObligations | 30.13M | 37.69M | 6.01M |
| CommonStockEquity | 22.89M | 95.71M | 202.22M |
| TotalCapitalization | 22.89M | 110.36M | 202.22M |
| TotalEquityGrossMinorityInterest | 22.89M | 95.71M | 202.22M |
| StockholdersEquity | 22.89M | 95.71M | 202.22M |
| RetainedEarnings | -350.39M | -275.64M | -161.00M |
| AdditionalPaidInCapital | 373.28M | 371.35M | 363.17M |
| CapitalStock | 2.00K | 2.00K | 47.00K |
| CommonStock | 2.00K | 2.00K | 47.00K |
| TotalLiabilitiesNetMinorityInterest | 32.49M | 67.23M | 23.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 28.40M | 52.54M | 8.36M |
| OtherNonCurrentLiabilities | 170.00K | 7.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 3.46M | 3.46M |
| NonCurrentDeferredRevenue | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 0.00 | 3.46M | 3.46M |
| LongTermDebtAndCapitalLeaseObligation | 28.40M | 48.91M | 4.89M |
| LongTermCapitalLeaseObligation | 28.40M | 34.26M | 4.89M |
| LongTermDebt | 14.65M | ||
| CurrentLiabilities | 4.08M | 14.69M | 14.79M |
| CurrentDeferredLiabilities | 0.00 | ||
| CurrentDeferredRevenue | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 1.72M | 3.43M | 1.13M |
| CurrentCapitalLeaseObligation | 1.72M | 3.43M | 1.13M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 125.00K | 680.00K | 4.40M |
| PayablesAndAccruedExpenses | 2.24M | 10.58M | 9.26M |
| CurrentAccruedExpenses | 1.68M | 8.61M | 5.52M |
| Payables | 559.00K | 1.97M | 3.74M |
| DuetoRelatedPartiesCurrent | 0.00 | ||
| TotalTaxPayable | 418.00K | 868.00K | |
| AccountsPayable | 141.00K | 1.10M | 3.74M |
| TotalAssets | 55.37M | 162.94M | 225.37M |
| TotalNonCurrentAssets | 29.53M | 88.39M | 82.82M |
| OtherNonCurrentAssets | 2.35M | 6.80M | 7.17M |
| NonCurrentDeferredAssets | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 32.90M | 50.96M |
| OtherIntangibleAssets | 32.90M | 32.90M | |
| Goodwill | 0.00 | 18.06M | |
| NetPPE | 27.18M | 48.69M | 24.69M |
| AccumulatedDepreciation | -275.00K | -9.29M | -4.23M |
| GrossPPE | 27.45M | 57.97M | 28.91M |
| Leases | 0.00 | 13.97M | 13.89M |
| ConstructionInProgress | 0.00 | 316.00K | 329.00K |
| OtherProperties | 26.58M | 36.90M | 8.90M |
| MachineryFurnitureEquipment | 869.00K | 6.79M | 5.79M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.85M | 74.55M | 142.55M |
| OtherCurrentAssets | 723.00K | 3.37M | 8.58M |
| PrepaidAssets | 8.58M | ||
| Receivables | 0.00 | 144.00K | 494.00K |
| DuefromRelatedPartiesCurrent | 0.00 | ||
| AccountsReceivable | 0.00 | 144.00K | 494.00K |
| CashCashEquivalentsAndShortTermInvestments | 25.12M | 71.04M | 133.48M |
| CashAndCashEquivalents | 25.12M | 71.04M | 133.48M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -31.50M | -77.03M | -83.12M |
| RepaymentOfDebt | -16.16M | -22.00K | -27.00K |
| IssuanceOfDebt | 0.00 | 14.74M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 118.58M | |
| CapitalExpenditure | -2.18M | -15.98M | |
| InterestPaidSupplementalData | 202.00K | 741.00K | 9.00K |
| EndCashPosition | 27.47M | 73.81M | 135.97M |
| BeginningCashPosition | 73.81M | 135.97M | 99.91M |
| ChangesInCash | -46.33M | -62.16M | 36.06M |
| FinancingCashFlow | -16.16M | 14.87M | 119.11M |
| CashFlowFromContinuingFinancingActivities | -16.16M | 14.87M | 119.11M |
| NetOtherFinancingCharges | -132.00K | -2.66M | |
| ProceedsFromStockOptionExercised | 0.00 | 289.00K | 3.22M |
| NetPreferredStockIssuance | 0.00 | ||
| PreferredStockIssuance | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 118.58M | |
| CommonStockIssuance | 0.00 | 118.58M | |
| NetIssuancePaymentsOfDebt | -16.16M | 14.72M | -27.00K |
| NetLongTermDebtIssuance | -16.16M | 14.72M | -27.00K |
| LongTermDebtPayments | -16.16M | -22.00K | -27.00K |
| LongTermDebtIssuance | 0.00 | 14.74M | 0.00 |
| InvestingCashFlow | 1.33M | -2.18M | -15.92M |
| CashFlowFromContinuingInvestingActivities | 1.33M | -2.18M | -15.92M |
| NetPPEPurchaseAndSale | 1.33M | -2.18M | -15.92M |
| SaleOfPPE | 1.33M | 0.00 | 62.00K |
| PurchaseOfPPE | 0.00 | -2.18M | -15.98M |
| OperatingCashFlow | -31.50M | -74.85M | -67.13M |
| CashFlowFromContinuingOperatingActivities | -31.50M | -74.85M | -67.13M |
| ChangeInWorkingCapital | -5.42M | -1.56M | -14.51M |
| ChangeInOtherWorkingCapital | -13.63M | ||
| ChangeInOtherCurrentLiabilities | -2.93M | 1.98M | -1.01M |
| ChangeInOtherCurrentAssets | 4.03M | 656.00K | -4.69M |
| ChangeInPayablesAndAccruedExpense | -8.79M | -2.02M | 7.43M |
| ChangeInAccruedExpense | -7.83M | 237.00K | 5.43M |
| ChangeInPayable | -956.00K | -2.26M | 2.00M |
| ChangeInAccountPayable | -956.00K | -2.26M | 2.26M |
| ChangeInPrepaidAssets | 2.12M | -2.53M | -3.22M |
| ChangeInReceivables | 143.00K | 350.00K | 601.00K |
| ChangesInAccountReceivables | 143.00K | 350.00K | 540.00K |
| OtherNonCashItems | 1.91M | 3.02M | 913.00K |
| StockBasedCompensation | 1.93M | 7.84M | 4.16M |
| AssetImpairmentCharge | 46.04M | 24.98M | 0.00 |
| DeferredTax | -3.46M | 0.00 | |
| DeferredIncomeTax | -3.46M | 0.00 | |
| DepreciationAmortizationDepletion | 1.52M | 5.51M | 2.30M |
| DepreciationAndAmortization | 1.52M | 5.51M | 2.30M |
| OperatingGainsLosses | 729.00K | 7.00K | -1.84M |
| GainLossOnSaleOfPPE | -637.00K | 7.00K | -28.00K |
| NetIncomeFromContinuingOperations | -74.75M | -114.65M | -58.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FNCH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|